Real-World Experience With Secukinumab for Hidradenitis Suppurativa: A Multicenter Retrospective Analysis of 263 Patients From the SECU-SPAIN Study

Background/objective: There is no consensus on the response rates of secukinumab, as findings from phase III trials differ from those reported in clinical-practice studies. This study aimed to assess the mid-term safety and efficacy profile of secukinumab in patients with moderate-to-severe Hidraden...

Descripción completa

Detalles Bibliográficos
Autores: Martorell, A., Garcias-Ladaria, Joan, Vilarrasa-Rull, E., Fernandez-Crehuet, P., Molina-Leyva, A., Mansilla, M., Garcia-Ruiz, R., Garbayo-Salmons, P., Ortiz-Salvador, J.M., Alfageme-Roldan, F., Garcias-Ladaria, J., Bassas-Vila, J., Fuertes-de-Vega, I., Carnero-Gonzalez, L., Almenara-Blasco, M., Torres-Navarro, I., Aguayo-Ortiz, R., Gil Pallares, P., Fornons-Servent, R., Gracia-Darder, Inés, Mora-Fernández, V., Corral, O., Pericet-Fernandez, L., Navarro, F., Haselgruber, S., Ochando-Ibernon, G., Menéndez-Parron, A., Masferrer, E., Gamissans, M., Solera-Talamante, M., Moya, M., Imbernon, A., Melgosa, J.
Tipo de recurso: artículo
Fecha de publicación:2026
País:España
Institución:Conselleria de Salut i Consum del Govern de les Illes Balears
Repositorio:Docusalut
Idioma:inglés
OAI Identifier:oai:docusalut.com:20.500.13003/26467
Acceso en línea:https://hdl.handle.net/20.500.13003/26467
Access Level:acceso abierto
Palabra clave:Antibodies, Monoclonal
Hidradenitis Suppurativa
Anticuerpos Monoclonales
Hidradenitis Supurativa
Anti Il17A
HS
Monoclonal antibody
Real-world evidence
Secukinumab
Descripción
Sumario:Background/objective: There is no consensus on the response rates of secukinumab, as findings from phase III trials differ from those reported in clinical-practice studies. This study aimed to assess the mid-term safety and efficacy profile of secukinumab in patients with moderate-to-severe Hidradenitis suppurativa (HS). Methods: This retrospective, multicenter study included patients with moderate-to-severe HS treated with secukinumab (300mg every four weeks) between 2020 and 2024. Eligible patients were aged ≥18 years, with a clinical diagnosis of moderate-to-severe HS, and a minimum follow-up of 24 weeks. Key exclusions included patients treated with nonstandard secukinumab dosing regimens or those with insufficient clinical data. The primary endpoints were achievement of HiSCR50 (≥50% reduction in the combined count of nodules and abscesses) at weeks 16 and 24). Secondary endpoints included achieving a ≥55% reduction in the International HS Severity Score (IHS4-55) and adverse events. Results: A total of 263 patients (49.4%, women; 50.6%, men; mean age, 41.8±13.2 years) were included. The most common HS phenotype was mixed (49.4%), and 55.1% had Hurley stage III disease. At weeks 16 and 24, a total of 57.4% and 63.6% of patients achieved HiSCR50, respectively. The mean IHS4 score dropped significantly from 16.7±10.0 at baseline to 7.6±5.6 at week 24 (p<0.0001). At weeks 16 and 24, 52% and 56% of patients achieved an IHS4-55 response. Secukinumab was discontinued in 14.5% of patients because of lack of efficacy or adverse events. Conclusions: Secukinumab demonstrated a significant safety and efficacy profile for patients with moderate-to-severe in a real-world setting, with better outcomes than those reported in earlier clinical trials. Response evaluation at both week 16 and 24 is crucial due to variations in treatment effectiveness.

Similares en LA Referencia